Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 8, 1999, Pages 549-554

  Moriearty, P L ^a   Seubert, P ^b   Galasko, D ^c   Markwell, S ^a   Unni, L ^a   Vicari, S ^a   Becker, R E ^a,d  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Athena Neurosciences Inc   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

1 Antichymotrypsin; A 42; Alzheimer's disease; ApoE protein; Monocytes; Tau protein

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; METRIFONATE; PLACEBO; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; MALE; NERVE DEGENERATION; SCORING SYSTEM;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; ELECTROPHORESIS; FEMALE; HUMANS; INTELLIGENCE TESTS; LEUKOCYTES; MALE; MONOCYTES; PHENOTYPE; TAU PROTEINS; TIME FACTORS; TRICHLORFON;

EID: 0032741510     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1999.21.8.794837     Document Type: Article

References (20)

1. Zubenko, G.S. Molecular neurobiology of Alzheimer's disease (syndrome?). Harvard Rev Psychiatry 1997, 5: 177-213.
2. Dickson, D.W. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997, 56: 321-39.
3. Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., DeLong, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
4. Kása, P., Rakonczay, Z., Gulya, K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997, 52: 511-35.
5. Roberson, M.R., Harrell, L.E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 1997, 25: 50-69.
6. Griffin, W.S.T., Sheng, J.G., Royston, M.C. et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998, 8: 65-72.
7. Farrer, L.A., Cupples, L.A., Haines, J.L. et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278: 1349-56.
8. Galasko, D., Chang, L., Motter, R. et al. High CSF tau and low A β 42 in the clinical diagnosis of Alzheimer's disease and relation to APO E genotype. Arch Neurol 1998, 55: 937-45.
9. Becker, R.E., Colliver, J.A., Markwell, S.J., Moriearty, PL., Unni, L.K., Vicari, S. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. Alzheimer Dis Assoc Disord 1998, 12: 54-7.
10. Cockrell, J.R., Folstein, M.F. Mini-mental state examination (MMSE). Psychopharmacol Bull 1988, 24: 689-92.
11. Poirier, J., Davignon, J., Bouthillier, D., Kogan, S., Bertrand, P., Gauthier, S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 697-9.
12. Skoog, I., Hesse, C., Fredman, P., Andreasson, Lo-A., Palmertz, B., Blennow, K. Apolipoprotein E in cerebrospinal fluid in 85-year old subjects. Arch Neurol 1997, 54: 267-72.
13. Becker, R.E., Colliver, J.A., Markwell, S.J., Moriearty, P.L., Unni, L.K., Vicari, S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996, 10: 124-31.
14. Pirttila, T., Mehta, P.D., Frey, H., Wisniewski, H.M. α1-Antichymotrypsin and IL-1 β are not increased in CSF or serum in Alzheimer's disease. Neurobiol Aging 1994, 15: 313-7.
15. Motter, R., Vigo-Pelfrey, C.V., Kholodenko, D. et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38: 643-8.
16. Tapiola, T., Overmyer, M., Lehtovirta, M. et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997, 8: 3961-3.
17. Galasko, D. CSF tau and A β 42: logical biomarkers for Alzheimer's disease? Neurobiol Aging 1998, 19: 117-9.
18. Becker, R.E., Moriearty, P., Unni, L., Vicari, S. Cholinesterase inhibitors as therapy in Alzheimer's disease: benefit to risk considerations in clinical application. In: Becker, R., Giacobini, E. (Eds.). Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston 1996: 257-66.
19. Aisen, P.S., Marin, D.B., Davis, K.L. Inflammatory processes -anti-inflammatory therapy. In: Becker, R., Giacobini, E. (Eds.). Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston 1996: 349-53.
20. Galasko, D., Clark, C., Chang, L., Miller, B., Green, R.C., Motter, R., Seubert, P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurol 1997, 48: 632-5.